Treatment of therapy-resistant perineal metastatic Crohn's disease after proctectomy using anti-tumor necrosis factor chimeric monoclonal antibody, cA2 - Report of two cases

  • HM van Dullemen*
  • , E de Jong
  • , F Slors
  • , GNJ Tytgat
  • , SJH van Denventer
  • *Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    63 Citations (Scopus)

    Abstract

    PURPOSE: Two young females with well-documented Crohn's disease and nonhealing perineal wounds following proctectomy compatible with "metastatic Crohn's disease" are described, We hypothesized that metastatic Crohn's disease would be a tumor necrosis factor-dependent inflammatory-reaction and have treated these two patients with the anti-tumor necrosis factor chimeric monoclonal antibody, cA2. MAIN FINDINGS: Administration of cA2 was followed by a rapid reduction of subjective and objective parameters of inflammation and caused a substantial reduction of the wound size, CONCLUSION: These preliminary data are consistent with a tumor necrosis factor-dependent inflammatory cause of Crohn's disease and its extraintestinal manifestations and provide support for targeting tumor necrosis factor in this condition.

    Original languageEnglish
    Pages (from-to)98-102
    Number of pages5
    JournalDISEASES OF THE COLON & RECTUM
    Volume41
    Issue number1
    Publication statusPublished - Jan-1998

    Keywords

    • Crohn's disease, metastatic
    • anti-tumor necrosis factor chimeric monoclonal antibody
    • proctectomy
    • perineal wound
    • tumor necrosis factor
    • FACTOR-ALPHA CA2
    • RHEUMATOID-ARTHRITIS
    • GRANULOMA-FORMATION

    Fingerprint

    Dive into the research topics of 'Treatment of therapy-resistant perineal metastatic Crohn's disease after proctectomy using anti-tumor necrosis factor chimeric monoclonal antibody, cA2 - Report of two cases'. Together they form a unique fingerprint.

    Cite this